Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000617509 | SCV000736911 | uncertain significance | Cardiovascular phenotype | 2017-09-13 | criteria provided, single submitter | clinical testing | The p.F24483L variant (also known as c.73447T>C), located in coding exon 184 of the TTN gene, results from a T to C substitution at nucleotide position 73447. The phenylalanine at codon 24483 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV001508099 | SCV001714023 | uncertain significance | not provided | 2020-01-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001508099 | SCV001814231 | likely benign | not provided | 2020-06-05 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001508099 | SCV004237408 | uncertain significance | not provided | 2023-03-23 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001508099 | SCV004701601 | uncertain significance | not provided | 2024-01-01 | criteria provided, single submitter | clinical testing | TTN: PM2, BP1 |
Laboratory of Diagnostic Genome Analysis, |
RCV001508099 | SCV001797484 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV001508099 | SCV001918227 | uncertain significance | not provided | no assertion criteria provided | clinical testing |